Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'LEVODOPA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1283 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nieuwboer, A; De Weerdt, W; Dom, R; Truyen, M; Janssens, L; Kamsma, Y
      The effect of a home physiotherapy program for persons with Parkinson's disease

      JOURNAL OF REHABILITATION MEDICINE
    2. Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Grosset, DG; MacMahon, DG; Playfer, J; Schapira, AHV; Stewart, D; Widliams, AC
      Updated guidelines for the management of Parkinson's disease

      HOSPITAL MEDICINE
    3. Bjarkam, CR; Sorensen, JC; Sunde, NA; Geneser, FA; Ostergaard, K
      New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders

      BIOGERONTOLOGY
    4. Muller, T; Benz, S; Bornke, C
      Delay of simple reaction time after levodopa intake

      CLINICAL NEUROPHYSIOLOGY
    5. Stefanova, ED; Kostic, VS; Ziropadja, L; Ocic, GG; Markovic, M
      Declarative memory in early Parkinson's disease: Serial position learning effects

      JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY
    6. Wooten, GF
      Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    7. Nutt, JG
      Motor fluctuations and dyskinesia in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    8. Jankovic, J; Tintner, R
      Dystonia and parkinsonism

      PARKINSONISM & RELATED DISORDERS
    9. Hwang, WJ; Calne, DB; Tsui, JKC; de la Fuente-Fernandez, R
      The long-term response to levodopa in dopa-responsive dystonia

      PARKINSONISM & RELATED DISORDERS
    10. Holmberg, B; Johnels, B; Ingvarsson, P; Eriksson, B; Rosengren, L
      CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes

      PARKINSONISM & RELATED DISORDERS
    11. Milanov, I
      A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor

      PARKINSONISM & RELATED DISORDERS
    12. Manyam, BV; Walters, AS; Keller, IA; Ghobrial, M
      Parkinsonism associated with autosomal dominant bilateral striopallidodentate calcinosis

      PARKINSONISM & RELATED DISORDERS
    13. Caraceni, T; Musicco, M
      Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study

      PARKINSONISM & RELATED DISORDERS
    14. Gimenez-Roldan, S; Mateo, D; Navarro, E; Gines, MM
      Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis

      PARKINSONISM & RELATED DISORDERS
    15. Myllyla, VV; Kultalahti, ER; Haapaniemi, H; Leinonen, M
      Twelve-month safety of entacapone in patients with Parkinson's disease

      EUROPEAN JOURNAL OF NEUROLOGY
    16. Oertel, WH
      Overview and introduction: conquering nocturnal complications in Parkinson's disease and restless legs syndrome - the role of continuous dopaminergicstimulation

      EUROPEAN JOURNAL OF NEUROLOGY
    17. Stiasny, K
      Handling the problem of augmentation in restless legs syndrome (RLS)

      EUROPEAN JOURNAL OF NEUROLOGY
    18. Shimbo, T; Hira, K; Takemura, M; Fukui, T
      Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan

      PHARMACOECONOMICS
    19. Rubenstein, LM; DeLeo, A; Chrischilles, EA
      Economic and health-related quality of life considerations of new therapies in Parkinson's disease

      PHARMACOECONOMICS
    20. Dodel, RC; Berger, K; Oertel, WH
      Health-related quality of life and healthcare utilisation in patients withParkinson's disease - Impact of motor fluctuations and dyskinesias

      PHARMACOECONOMICS
    21. Le, WD; Jankovic, J
      Are dopamine receptor agonists neuroprotective in Parkinson's disease?

      DRUGS & AGING
    22. Sajjan, AG; Melwanki, MB; Seetharamappa, J
      Spectrophotometric determination of certain vicinal dihydroxybenzene derivatives with sodium bismuthate

      JOURNAL OF ANALYTICAL CHEMISTRY
    23. Furlanut, M; Furlanut, M; Benetello, P
      Monitoring of L-dopa concentrations in Parkinson's disease

      PHARMACOLOGICAL RESEARCH
    24. Lee, JI; Shin, HJ; Nam, DH; Kim, JS; Hong, SC; Shin, HJ; Park, K; Eoh, W; Kim, JH; Lee, WY
      Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine

      JOURNAL OF KOREAN MEDICAL SCIENCE
    25. Johansson, PA; Andersson, M; Andersson, KE; Cenci, MA
      Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia

      NEUROBIOLOGY OF DISEASE
    26. Lieberman, A; Minagar, A; Pinter, MM
      The efficacy of pramipexole in the treatment of Parkinson's disease

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    27. Westin, JE; Andersson, M; Lundblad, M; Cenci, MA
      Persistent changes in striatal gene expression induced by long-term L-DOPAtreatment in a rat model of Parkinson's disease

      EUROPEAN JOURNAL OF NEUROSCIENCE
    28. Iravani, MM; Costa, S; Jackson, MJ; Tel, BC; Cannizzaro, C; Pearce, RKB; Jenner, P
      GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed commonmarmosets

      EUROPEAN JOURNAL OF NEUROSCIENCE
    29. Eckardt, KM; Trenkwalder, C
      The restless legs syndrome

      PHLEBOLOGIE
    30. Torner, C; Aguilar-Roblero, R
      Asynchrony in the diurnal rhythms of dopaminergic D-2 receptors in different brain regions of the rat

      BIOLOGICAL RHYTHM RESEARCH
    31. Onla-or, S; Winstein, CJ
      Function of the 'direct' and 'indirect' pathways of the basal ganglia motor loop: evidence from reciprocal aiming movements in Parkinson's disease

      COGNITIVE BRAIN RESEARCH
    32. Remme, WJ
      Dopaminergic agents in heart failure: Rebirth of an old concept

      CARDIOVASCULAR DRUGS AND THERAPY
    33. Slaughter, JR; Slaughter, KA; Nichols, D; Holmes, SE; Martens, RP
      Prevalence, clinical manifestations, etiology, and treatment of depressionin Parkinson's disease

      JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
    34. Amaki, SK; Oguchi, Y; Ogata, T; Suzuki, T; Akeo, K; Hiramitsu, T
      L-DOPA produced nitric oxide in the vitreous and caused greater vasodilation in the choroid and the ciliary body of melanotic rats than in those of amelanotic rats

      PIGMENT CELL RESEARCH
    35. Shetty, P; Atallah, MT; Shetty, K
      Enhancement of total phenolic, L-dopa and proline contents in germinating fava bean (Vicia faba) in response to bacterial elicitors

      FOOD BIOTECHNOLOGY
    36. Marin, C; Jimenez, A; Bonastre, M; Vila, M; Agid, Y; Hirsch, EC; Tolosa, E
      LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats

      SYNAPSE
    37. Danielsen, EH; Smith, D; Hermansen, F; Gjedde, A; Cumming, P
      Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo

      SYNAPSE
    38. Ruottinen, HM; Niinivirta, M; Bergman, J; Oikonen, V; Solin, O; Eskola, O; Eronen, E; Sonninen, P; Rinne, UK
      Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging

      SYNAPSE
    39. Saletu, M; Anderer, P; Saletu, B; Hauer, C; Mandl, M; Semler, B; Saletu-Zyhlarz, G
      Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    40. Hardoff, R; Sula, M; Tamir, A; Soil, A; Front, A; Badarna, S; Honigman, S; Giladi, N
      Gastric emptying time and gastric motility in patients with Parkinson's disease

      MOVEMENT DISORDERS
    41. Apartis, E; Tison, F; Arne, P; Jedynak, CP; Vidailhet, M
      Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor

      MOVEMENT DISORDERS
    42. Gordon, PH; Frucht, SJ
      Neuroleptic malignant syndrome in advanced Parkinson's disease

      MOVEMENT DISORDERS
    43. Nurmi, E; Ruottinen, HM; Bergman, J; Haaparanta, M; Solin, O; Sonninen, P; Rinne, JO
      Rate of progression in Parkinson's disease: A 6-[F-18]fluoro-L-dopa PET study

      MOVEMENT DISORDERS
    44. Maratos, EC; Jackson, MJ; Pearce, RKB; Jenner, P
      Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)

      MOVEMENT DISORDERS
    45. Rascol, O; Arnulf, I; Paul, HPS; Brefel-Courbon, C; Vidailhet, M; Thalamas, C; Bonnet, AM; Descombes, S; Bejjani, B; Fabre, N; Montastruc, JL; Agid, Y
      Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

      MOVEMENT DISORDERS
    46. Goto, S; Kunitoku, N; Hamasaki, T; Nishikawa, S; Ushio, Y
      Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: Long-term follow-up study

      MOVEMENT DISORDERS
    47. Datla, KP; Blunt, SB; Dexter, DT
      Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, inrats with partial 6-OHDA or FeCl3 nigrostriatal lesions

      MOVEMENT DISORDERS
    48. Muriel, MP; Agid, Y; Hirsch, E
      Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease

      MOVEMENT DISORDERS
    49. Ahlskog, JE; Muenter, MD
      Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

      MOVEMENT DISORDERS
    50. Hutton, JT; Metman, LV; Chase, TN; Juncos, JL; Koller, WC; Pahwa, R; LeWitt, PA; Samii, A; Tsui, JKC; Calne, DB; Waters, CH; Calabrese, VP; Bennett, JP; Barrett, R; Morris, JL
      Transdermal dopaminergic D-2 receptor agonist therapy in parkinson's disease with n-0923 TDS: A double-blind, placebo-controlled study

      MOVEMENT DISORDERS
    51. Montastruc, JL; Desboeuf, K; Lapeyre-Mestre, M; Senard, JM; Rascol, O; Brefel-Courbon, C
      Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

      MOVEMENT DISORDERS
    52. Del Dotto, P; Pavese, N; Gambaccini, G; Bernardini, S; Metman, LV; Chase, TN; Bonuccelli, U
      Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

      MOVEMENT DISORDERS
    53. Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M
      Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

      MOVEMENT DISORDERS
    54. Petzinger, GM; Quik, M; Ivashina, E; Jakowec, MW; Jakubiak, M; Di Monte, D; Langston, JW
      Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate

      MOVEMENT DISORDERS
    55. Stocchi, F; Vacca, L; Berardelli, A; De Pandis, F; Ruggieri, S
      Long-duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half-life

      MOVEMENT DISORDERS
    56. Camicioli, R; Grossmann, SJ; Spencer, PS; Hudnell, K; Anger, WK
      Discriminating mild parkinsonism: Methods for epidemiological research

      MOVEMENT DISORDERS
    57. Kemoun, G; Defebvre, L
      Gait disorders in Parkinson's disease - Clinical evaluation and analysis of posture, initiation and stabilized gait

      PRESSE MEDICALE
    58. Ahlskog, JE
      Parkinson's disease: Medical and surgical treatment

      NEUROLOGIC CLINICS
    59. Marcolino-Junior, LH; Teixeira, MFS; Pereira, AV; Fatibello, O
      Flow Injection Determination of levodopa in tablets using a solid-phase reactor containing lead(IV) dioxide immobilized

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    60. Grange, S; Holford, NHG; Guentert, TW
      A pharmacokinetic model to predict the PK interaction of l-dopa and benserazide in rats

      PHARMACEUTICAL RESEARCH
    61. Kratz, T; Wallesch, CW
      Pathological laughter and crying

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    62. Sorbera, LA; Martin, L; Leeson, PA; Castaner, J
      Etilevodopa - Antiparkinsonian - Dopamine precursor

      DRUGS OF THE FUTURE
    63. Jankovic, J
      Parkinson's diseasetherapy: treatment of early and late disease

      CHINESE MEDICAL JOURNAL
    64. de la Fuente-Fernandez, R; Lu, JQ; Sossi, V; Jivan, S; Schulzer, M; Holden, JE; Lee, CS; Ruth, TJ; Calne, DB; Stoessl, AJ
      Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

      ANNALS OF NEUROLOGY
    65. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    66. Gimenez-Roldan, S; Esteban, EM; Mateo, D
      Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: Open label pilot responses to three different dose-ratios

      CLINICAL NEUROPHARMACOLOGY
    67. Factor, SA; Molho, ES; Feustel, PJ; Brown, DL; Evans, SM
      Long-term comparative experience with tolcapone and entacapone in advancedParkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    68. Camicioli, R; Lea, E; Nutt, JG; Sexton, G; Oken, BS
      Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: A pilot study

      CLINICAL NEUROPHARMACOLOGY
    69. Minea, D; Varga, I; Falup-Pecurariu, C; de Mey, C; Retzow, A; Althaus, M
      Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    70. Heikkinen, H; Nutt, JG; LeWitt, PA; Koller, WC; Gordin, A
      The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    71. Metman, LV; Gillespie, M; Farmer, C; Bibbiani, F; Konitsiotis, S; Morris, M; Shill, H; Bara-Jimenez, W; Mouradian, MM; Chase, TN
      Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    72. Greenamyre, JT
      Glutamatergic influences on the basal ganglia

      CLINICAL NEUROPHARMACOLOGY
    73. Micallef-Roll, J; Rihet, P; Hasbroucq, T; Possamai, C; Blin, O
      Levodopa-induced drowsiness in healthy volunteers: Results of a choice reaction time test combined with a subjective evaluation of sedation

      CLINICAL NEUROPHARMACOLOGY
    74. Djaldetti, R; Rosmarin, V; Ziv, I; Melamed, E
      The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    75. Sanabria, J; Ruiz, PG; Gutierrez, R; Marquez, F; Escobar, P; Gentil, M; Cenjor, C
      The effect of levodopa on vocal function in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    76. Offen, D; Panet, H; Galili-Mosberg, R; Melamed, E
      Catechol-O-methyltransferase decreases levodopa toxicity in vitro

      CLINICAL NEUROPHARMACOLOGY
    77. Lyytinen, J; Sovijarvi, A; Kaakkola, S; Gordin, A; Teravainen, H
      The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-dopa-treated patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    78. Djaldetti, R; Melamed, E
      New therapies for Parkinson's disease

      JOURNAL OF NEUROLOGY
    79. Baas, H; Zehrden, F; Selzer, R; Kohnen, R; Loetsch, J; Harder, S
      Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease

      CLINICAL PHARMACOKINETICS
    80. Bezard, E; Boraud, T; Chalon, S; Brotchie, JM; Guilloteau, D; Gross, CE
      Pallidal border cells: An anatomical and electrophysiological study in the1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey

      NEUROSCIENCE
    81. Muller, T; Woitalla, D; Hauptmann, B; Fowler, B; Kuhn, W
      Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease

      NEUROSCIENCE LETTERS
    82. Itokazu, N; Yamamoto, K; Ouchi, Y; Cyong, JC
      Establishment of L-3,4-dihydroxyphenilalaninde-induced pharmacological dementia model mouse

      NEUROSCIENCE LETTERS
    83. Lee, MS; Lyoo, CH; Ulmanen, I; Syvanen, AC; Rinne, JO
      Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

      NEUROSCIENCE LETTERS
    84. Bayas, A; Kornhuber, J; Naumann, M
      Atypical neuroleptics and new antidepressants in the treatment of neurological disorders

      AKTUELLE NEUROLOGIE
    85. Zeng, BY; Pearce, RKB; MacKenzie, GM; Jenner, P
      Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study

      JOURNAL OF NEURAL TRANSMISSION
    86. Brusa, L; Pierantozzi, M; Peppe, A; Altibrandi, MG; Giacomini, P; Mazzone, P; Stanzione, P
      Deep Brain Stimulation (DBS) attentional effects parallel those of l-dopa treatment

      JOURNAL OF NEURAL TRANSMISSION
    87. Fredriksson, A; Danysz, W; Quack, G; Archer, T
      Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

      JOURNAL OF NEURAL TRANSMISSION
    88. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
      High-dose therapy with ropinirole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    89. Giladi, N; Treves, TA; Simon, ES; Shabtai, H; Orlov, Y; Kandinov, B; Paleacu, D; Korczyn, AD
      Freezing of gait in patients with advanced Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    90. Haasio, K; Sopanen, L; Vaalavirta, L; Linden, IB; Heinonen, EH
      Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat

      JOURNAL OF NEURAL TRANSMISSION
    91. Tuite, P; Ebbitt, B
      Dopamine agonists

      SEMINARS IN NEUROLOGY
    92. Hanson, MR; Galvez-Jimenez, N
      Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease

      SEMINARS IN NEUROLOGY
    93. Mehta, A; Bot, G; Reisine, T; Chesselet, MF
      Endomorphin-1: Induction of motor behavior and lack of receptor desensitization

      JOURNAL OF NEUROSCIENCE
    94. Morris, ME; Huxham, F; McGinley, J; Dodd, K; Iansek, R
      The biomechanics and motor control of gait in Parkinson disease

      CLINICAL BIOMECHANICS
    95. Hurley, MJ; Mash, DC; Jenner, P
      Dopamine D-1 receptor expression in human basal ganglia and changes in Parkinson's disease

      MOLECULAR BRAIN RESEARCH
    96. Chassain, C; Eschalier, A; Durif, F
      Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP

      JOURNAL OF NEUROSCIENCE METHODS
    97. Joyce, JN
      Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

      PHARMACOLOGY & THERAPEUTICS
    98. Contin, M; Riva, R; Martinelli, P; Albani, F; Avoni, P; Baruzzi, A
      Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach

      THERAPEUTIC DRUG MONITORING
    99. Willems, M; Quartero, AO; Numans, ME
      How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study

      DIGESTIVE DISEASES AND SCIENCES
    100. Najib, J
      Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease

      CLINICAL THERAPEUTICS


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/02/20 alle ore 08:33:09